Cargando…

Interleukin-10 gene down-expression in circulating mononuclear cells during infusion of drotrecogin-α activated: a pilot study

INTRODUCTION: The purpose of this study was to investigate the gene expression of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and interleukin-10 (IL-10) in circulating mononuclear cells harvested from septic shock patients on drotrecogin-α activated (DAA) in order to determine whet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lavaux, Thomas, Bilbault, Pascal, Launoy, Anne, Gaub, Marie-Pierre, Oudet, Pierre, Schneider, Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219256/ https://www.ncbi.nlm.nih.gov/pubmed/20825636 http://dx.doi.org/10.1186/cc9252

Ejemplares similares

Drotrecogin alfa (activated): down and not out, but not really in either
por: Friedrich, Jan O, et al.
Publicado: (2006)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping
por: Beau-Faller, M, et al.
Publicado: (2009)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
por: Mackenzie, S, et al.
Publicado: (2004)

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
por: Laterre, Pierre-François, et al.
Publicado: (2003)

Drotrecogin alfa (activated): real-life use and outcomes for the UK
por: Rowan, Kathryn M, et al.
Publicado: (2008)

Drotrecogin alfa: start early, ensure response, stop early!
por: Jog, S, et al.
Publicado: (2008)

Drotrecogin alfa (activated): a single-centre experience of 110 patients
por: Fletcher, S, et al.
Publicado: (2010)

Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
por: Samama, Charles Marc, et al.
Publicado: (2011)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
por: Schuerholz, T, et al.
Publicado: (2004)

Induction of interleukin-10 during extracorporeal circulation
por: Khalighi, K, et al.
Publicado: (1999)

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
por: Friedrich, Jan O, et al.
Publicado: (2006)

Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis
por: Jamdar, Saurabh, et al.
Publicado: (2005)

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
por: Rowan, K, et al.
Publicado: (2007)

A large, single-centre UK registry of drotrecogin alfa-activated use
por: Macchiavello, L, et al.
Publicado: (2007)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
por: Shulman, R, et al.
Publicado: (2005)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

The Use of Drotrecogin Alfa (activated) in a Patient With Severe Acute Respiratory Syndrom
por: Farooq, Warda, et al.
Publicado: (2003)

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
por: Laterre, Pierre-François, et al.
Publicado: (2008)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)

Case report: short time reversible myocardial dysfunction in sepsis treated with drotrecogin alpha
por: Costa-Filho, RC, et al.
Publicado: (2003)

Drotrecogin alfa (activated) ... a sad final fizzle to a roller-coaster party
por: Angus, Derek C
Publicado: (2012)

Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
por: Vedantham, R, et al.
Publicado: (2007)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

Transcriptional profiling of circulating mononuclear cells from patients with chronic obstructive pulmonary disease receiving mesenchymal stromal cell infusions
por: Armitage, Jesse D., et al.
Publicado: (2021)

Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma
Publicado: (1989)

Recombinant horse interleukin-4 and interleukin-10 induced a mixed inflammatory cytokine response in horse peripheral blood mononuclear cells
por: Saini, Sheetal, et al.
Publicado: (2019)

Interferon-gamma and interleukin-10 production by mononuclear cells from patients with advanced head and neck cancer
por: Conti-Freitas, Luiz C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jt2sgdvmjv5jajf1qd01a3ccu6